Esperion Therapeutis.Inc. sell Northland Securities
Start price
16.03.23
/
50%
€1.91
Target price
16.03.24
-
Performance (%)
-25.50%
Price
23.03.23
€1.42
Summary
This prediction is currently active. The price of Esperion Therapeutis.Inc. has decreased since the start of the prediction. Compared to the start price this results in a performance of -25.50%. This prediction currently runs until 16.03.24. The prediction end date can be changed by Northland_Securities at any time. Northland_Securities has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w |
|---|---|
| Esperion Therapeutis.Inc. | -20.252% |
| iShares Core DAX® | 0.284% |
| iShares Nasdaq 100 | -0.713% |
| iShares Nikkei 225® | 0.598% |
| iShares S&P 500 | -2.171% |
Comments by Northland_Securities for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
Esperion Therapeutics, Inc. (NASDAQ: ESPR) was downgraded by analysts at Northland Securities from a "market perform" rating to an "underperform" rating.
Ratings data for ESPR provided by MarketBeat
